Lupus Nephritis Clinical Trial
Official title:
Multicenter Prospective Cohort of Kidney Biopsy for Glomerular Disease Research
Glomerulonephritis (GN) generates an enormous individual and social economic burden. However,
the therapeutic options are largely based on clinical and pathological parameters and the
individual response to therapy or prognosis is uncertain.
Recently, along with advances in molecular analysis and computational bioinformatics, genomic
data from human renal biopsies could provide a strong foundation for the future of precision
medicine in nephrology.
In response to a request for applications by the Ministry of Health and Welfare of Korea for
the creation of Clinical Research Registry, multi-center N network has been established for
prospective cohort with kidney biopsy samples (KORNERSTONE).
Through this Network the investigators hope to understand the fundamental biology of
glomerulonephritis and aim to bank long-term observational data and corresponding biological
data including genomic data from kidney tissues, and kidney pathologic data which is
digitalized This database is archived to a web-based platform to access easily and further
enrich for researchers.
Glomerulonephritis (GN) such as Minimal change disease (MCD), focal segmental
glomerulosclerosis (FSGS), Membranous nephropathy (MN), and Immunoglobulin A nephropathy
(IgAN) has quite a common clinical presentation often results in renal insufficiency which
generates an enormous individual and social economic burden.
However, the therapeutic options are largely based on clinical and pathological parameters
and the individual response to therapy or prognosis is uncertain.
Recently, along with advances in molecular analysis and computational bioinformatics, genomic
data from human renal biopsies could provide a strong foundation for the future of precision
medicine in nephrology.
In response to a request for applications by the Ministry of Health and Welfare of Korea for
the creation of Clinical Research Registry, a number of universities joined together to
establish Korean Kidney Biopsy Network (KORNERSTONE).
Through this Network the investigators hope to understand the fundamental biology of
glomerulonephritis and aim to bank long-term observational data and corresponding biological
data including genomic data from kidney tissues, and kidney pathologic data which is
digitalized This database is archived to a web-based platform to access easily and further
enrich for researchers.
============ <Patient clinical data will be collected as follows>
1. Blood tests: CBC, Chemistry (Ca, P, Glucose, Total protein, Albumin, Uric acid),
Electrolyte, Renal function (BUN, Creatinine, eGFR), Liver function (AST, ALT)
2. Immunologic blood tests: Complement 3, Complement 4, ASO, RF, Cryoglobulin, dsDNA, ANA
3. Urine tests: Urinalysis, Urine protein, Urine albumin, Urine creatinine
4. Radiologic tests: Kidney USG, Abdominal-pelvis computed tomography
5. Pathologic results
6. Treatment informations: treatment status, drug type, treatment duration
7. Quality of life questionnaire: Kidney Disease and Quality of Life Short Form survey
(adults), PedsQL 4.0 Generic Core Scales (pediatrics)
8. Dietary questionnaire
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02936375 -
The Iguratimod Effect on Lupus Nephritis (IGeLU)
|
Phase 2 | |
Completed |
NCT03597464 -
Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin
|
Phase 3 | |
Recruiting |
NCT01226147 -
Efficacy and Safety of Tamibarotene(AM80) for Lupus Nephritis
|
Phase 2 | |
Completed |
NCT01206569 -
Long-Acting Tacrolimus for the Treatment of Resistant Lupus Nephritis
|
Phase 4 | |
Active, not recruiting |
NCT00569101 -
A Pilot Study for the Efficacy and Safety of Tacrolimus in the Treatment of Refractory Lupus Nephritis
|
Phase 2 | |
Terminated |
NCT00368264 -
TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL )
|
Phase 2/Phase 3 | |
Completed |
NCT00298506 -
Study to Assess the Efficacy and Safety of FK506 Combined With Mycophenolate Mofetil (MMF) in Lupus Nephritis (III/IV/V)
|
N/A | |
Completed |
NCT00371319 -
Comparing the Efficacy of Tacrolimus and Mycophenolate Mofetil for the Initial Therapy of Active Lupus Nephritis
|
Phase 4 | |
Completed |
NCT00094380 -
Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)
|
Phase 1/Phase 2 | |
Terminated |
NCT04376827 -
A Study of Guselkumab in Participants With Active Lupus Nephritis
|
Phase 2 | |
Completed |
NCT03610516 -
Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Lupus Nephritis.
|
Phase 2 | |
Recruiting |
NCT03526042 -
Angiotensin-II Receptor Antibodies Blockade With Losartan in Patients With Lupus Nephritis
|
N/A | |
Withdrawn |
NCT03859570 -
Pentoxifylline in Lupus Nephritis
|
Phase 4 | |
Completed |
NCT03664908 -
Detection of Anti-glomerular Basement Membrane Antibodies (Anti-GBM): a Promising Biomarker for Lupus Nephritis (LN)?
|
N/A | |
Completed |
NCT01085097 -
A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis
|
Phase 2 | |
Active, not recruiting |
NCT05704088 -
SGLT2 Inhibitors Between Reno Protective Effects and Impact on Bone and Mineral Disease Among Lupus Nephritis Patients
|
Phase 4 | |
Not yet recruiting |
NCT06429800 -
A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Lupus Nephritis
|
Phase 1 | |
Recruiting |
NCT02226341 -
ACTHar in the Treatment of Lupus Nephritis
|
Phase 4 | |
Recruiting |
NCT02453997 -
Mycophenolic Acid Pharmacokinetics and Pharmacogenomics in Lupus Nephritis
|
N/A | |
Completed |
NCT01470183 -
Lupus Nephritis Biomarker Study: Baseline Characteristics of Patients
|
N/A |